# A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

> **NCT04147351** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 22 (actual)

## Conditions studied

- NSCLC Stage IIIB~IV

## Interventions

- **DRUG:** Atezolizumab Injection; bevacizumab Injection

## Key facts

- **NCT ID:** NCT04147351
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-10
- **Primary completion:** 2026-02-04
- **Final completion:** 2026-02-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147351, "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04147351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*